Descriptive, Post-marketing, Passive Surveillance Safety Study of Menactra Vaccine
This trial is active, not recruiting.
|Treatment||none administered in this study|
|Start date||July 2005|
|End date||May 2013|
|Trial size||20000 participants|
|Trial identifier||NCT00254995, MTA30|
To further characterize the vaccine safety profile and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.
Male or female participants of any age.
Inclusion Criteria: - Receipt of Menactra vaccine during the study period. Exclusion Criteria: - None
|Official title||Post-licensure Safety Surveillance Study of Routine Use of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra ™)|
Call for more information